The 17th St Gallen International Breast Cancer Consensus Conference in 2021 was held
virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in …

Simple Summary Breast cancer is the most-commonly diagnosed malignant tumor in women
in the world, as well as the first cause of death from malignant tumors. The incidence of …

Background The addition of pembrolizumab to neoadjuvant chemotherapy led to a
significantly higher percentage of patients with early triple-negative breast cancer having a …

Background Preferred neoadjuvant regimens for early-stage triple-negative breast cancer
(TNBC) include anthracycline-cyclophosphamide and taxane-based chemotherapy …

Background Adjuvant and neoadjuvant breast cancer treatments can reduce breast cancer
mortality but may increase mortality from other causes. Information regarding treatment …

Background Poly (adenosine diphosphate–ribose) polymerase inhibitors target cancers with
defects in homologous recombination repair by synthetic lethality. New therapies are …

Background Previous trials showed promising antitumor activity and an acceptable safety
profile associated with pembrolizumab in patients with early triple-negative breast cancer …

Breast cancer is the most common cancer diagnosed in females throughout the entire world,
and it is also the primary reason why people lose their lives due to malignant tumors. The …

Background For postmenopausal women with hormone-receptor–positive breast cancer, the
most effective duration for adjuvant therapy with an aromatase inhibitor remains unclear …

In recent decades, the increasing interest in the field of immunotherapy has fostered an
intense investigation of the breast cancer (BC) immune microenvironment. In this context …